Common mechanisms of melanoma progression and treatment resistance
The common mechanisms of melanoma progression and treatment resistance. PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are the most characterized tumor growth/treatment resistance-driving signals in melanoma. The activation of PI3K/AKT/mTOR is tightly controlled via a multistep process that can be initiated through tyrosine kinase receptors (RTKs) such as IGF-1R. The stimulation of IGF-1R by its ligand triggers the activation of PI3K via their catalytic (p110) and regulatory (p85) subunits leading to the conversion of phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) allowing PDK1 to phosphorylate the tyrosine 308 (T308) residue and mTORC2 to phosphorylate tyrosine 473 (T473) in the activation loop of AKT. Activated AKT then activates mTORC1 that, in turn, enhances the activation of the eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), and ribosomal protein S6 kinase (S6K). The activation of the Ras/RAF/MEK/ERK signaling pathway is mediated by the stimulation of epidermal growth factor (EGF) by its ligand for BRAF wild type or by active mutation in the cells bearing a NRAS mutation. The treatment of melanoma cells bearing BRAFV600E with specific inhibitors (e.g., dabrafenib) stimulates melanoma cells to overcome the inhibitory effect of BRAF through the generation of BRAF isoforms via alternative splicing. Treatment of patients with a NRAS mutation (NRASQ61R) with MEK inhibitors (e.g., trametinib) generates ERK negative feedback effects on RAS, which creates a bypass mechanism through activation of ARAF and/or CRAF to replace functional BRAF